EUVIMEDEUVIMED entdecken
Klinische Studie (Phase IV)Multizentrische StudieOpen Access · CC BY-NC 4.0

Two Years of Ocrelizumab Treatment in Black and Hispanic People with Multiple Sclerosis in CHIMES : A Single‐Arm Clinical Trial

Lilyana Amezcua, Anthony T Reder iD, Evanthia Bernitsas iD, Nancy L Monson iD, Timothy Vartanian, Gregory F Wu, Mansoor Saleh, Annette Okai, Ahmed Z Obeidat iD, Dilraj Sokhi, Rikisha Parekh, Jinglan Pei und 5 weitere

Annals of Neurology · 2026

DOI: 10.1002/ana.78290 ↗

Kurz gefasst

Klinische Studie (Phase IV) in der Zeitschrift Annals of Neurology, 2026. Verfasst von Lilyana Amezcua und 16 weiteren Autor:innen. Beteiligte Einrichtung: Keck School of Medicine, University of Southern California, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Black or African American, Hispanic or Latino, Immunologic Factors. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the effectiveness and safety of ocrelizumab in self‐identified black and Hispanic people with relapsing multiple sclerosis.

Methods

The Characterization of Ocrelizumab in Minorities with Multiple Sclerosis (CHIMES) trial, a prospective, open‐label, single‐arm, phase 4 study, intentionally recruited underrepresented populations in the US, Puerto Rico, and Kenya. Black and Hispanic people with relapsing multiple sclerosis aged 18–65 years with Expanded Disability Status Scale score 0–5.5 received ocrelizumab for 2 years. The primary endpoint was the proportion of participants with no evidence of disease activity in 3 components at week 48: protocol‐defined relapse, 24‐week confirmed disability progression, and disease activity on magnetic resonance imaging.

Results

Of 113 black and 69 Hispanic people with relapsing multiple sclerosis, most were women (72%), with a mean age of 35.5 (SD 10.5) years, body mass index of 31.0 (SD 7.4) kg/m 2 , and Expanded Disability Status Scale score of 2.4 (SD 1.4). Genetic ancestry aligned with self‐identified race or ethnicity. At week 48, 50.5% of CHIMES participants had no evidence of disease activity, including 94.5% free from 24‐week confirmed disability progression, 95.1% free from relapse, 95.6% free from T1‐contrast‐enhancing lesions, and 52.7% free from new/enlarging T2 lesions. Serious adverse events were experienced by 8.2%, and 2.2% discontinued treatment. Infusion‐related reactions were more frequent in Hispanic versus black participants (42.0% vs 29.2%), whereas gastrointestinal adverse events were more frequent in black versus Hispanic participants (23.0% vs 1.4%).

Interpretation

Ocrelizumab treatment controlled disease activity in black and Hispanic people with relapsing multiple sclerosis. Results were consistent with pivotal ocrelizumab trials, supporting ocrelizumab's effectiveness and tolerability in these populations. ANN NEUROL 2026;100:793–807

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedBlack or African AmericanHispanic or LatinoImmunologic FactorsMultiple Sclerosis, Relapsing-RemittingAdolescentAdultFemaleHumansMaleMiddle AgedYoung AdultDisease ProgressionProspective StudiesTreatment Outcome

Substanzen

Antibodies, Monoclonal, HumanizedImmunologic Factorsocrelizumab

Autor:innen und Institutionen

  • Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
  • University of Chicago Medicine, Chicago, Illinois, USA.
  • Department of Neurology, Creighton University School of Medicine, Omaha, Nebraska, USA.
  • University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Feil Family Brain & Mind Research Institute, Weill Cornell Medicine, New York, New York, USA.
  • Washington University in St Louis, St Louis, Missouri, USA.

ORCID-Profile: Anthony T Reder, Evanthia Bernitsas, Nancy L Monson, Ahmed Z Obeidat, Christopher Harp

Zitieren

APA

Amezcua, L., Reder, A. T., Bernitsas, E., Monson, N. L., Vartanian, T., Wu, G. F., Saleh, M., Okai, A., Obeidat, A. Z., Sokhi, D., Parekh, R., Pei, J., Harp, C., Clayton, D., Abioye, I., Williams, M. J., & CHIMES Study Group (2026). Two Years of Ocrelizumab Treatment in Black and Hispanic People with Multiple Sclerosis in CHIMES : A Single‐Arm Clinical Trial. Annals of Neurology. https://doi.org/10.1002/ana.78290

Vancouver

Amezcua L, Reder AT, Bernitsas E, Monson NL, Vartanian T, Wu GF, et al. Two Years of Ocrelizumab Treatment in Black and Hispanic People with Multiple Sclerosis in CHIMES : A Single‐Arm Clinical Trial. Annals of Neurology. 2026. doi:10.1002/ana.78290

BibTeX
@article{Amezcua2026,
  author = {Amezcua, Lilyana and Reder, Anthony T and Bernitsas, Evanthia and Monson, Nancy L and Vartanian, Timothy and Wu, Gregory F and Saleh, Mansoor and Okai, Annette and Obeidat, Ahmed Z and Sokhi, Dilraj and Parekh, Rikisha and Pei, Jinglan and Harp, Christopher and Clayton, David and Abioye, Ibraheem and Williams, Mitzi J and CHIMES Study Group, CHIMES Study Group},
  title = {Two Years of Ocrelizumab Treatment in Black and Hispanic People with Multiple Sclerosis in CHIMES : A Single‐Arm Clinical Trial},
  journal = {Annals of Neurology},
  year = {2026},
  doi = {10.1002/ana.78290}
}
Kostenlos starten →